191.04
  Price3.62%   +6.68
(After Hours: 191.00 -0.0400 -0.02%)
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
TOUSI SUSAN H SVP, Chief Commercial Officer Jun 10 Sale 214.85 250 53,712 41,833
Dadswell Charles SVP & General Counsel Apr 28 Sale 300.13 368 110,448 7,427
Hoyt Aimee L SVP, Chief People Officer Apr 12 Sale 350.51 2,474 867,173 5,342
Febbo Phillip G. SVP Chief Medical Officer Apr 06 Sale 360.01 1,988 715,700 5,774
Dadswell Charles SVP & General Counsel Mar 28 Sale 342.83 368 126,161 7,795
Hoyt Aimee L SVP, Chief People Officer Feb 22 Option Exercise 0 3,421 0 6,678
TOUSI SUSAN H SVP, Chief Commercial Officer Feb 22 Option Exercise 0 4,561 0 43,891
deSouza Francis A President and CEO Feb 22 Option Exercise 0 19,383 0 88,587
Febbo Phillip G. SVP Chief Medical Officer Feb 22 Option Exercise 0 2,851 0 5,866
SAMAD SAM SVP and CFO Feb 22 Option Exercise 0 4,561 0 11,023
Pegels Kevin Carl Chief of Global Operations Feb 22 Option Exercise 0 1,065 0 5,910
GOSWAMI JOYDEEP SVP Corp Business Development Feb 22 Option Exercise 0 3,979 0 7,824
Dadswell Charles SVP & General Counsel Feb 22 Option Exercise 0 4,561 0 7,889
TOUSI SUSAN H SVP, Chief Commercial Officer Jan 12 Sale 425.00 800 340,000 39,274
TOUSI SUSAN H SVP, Chief Commercial Officer Dec 28 Sale 387.06 100 38,706 40,074
Dadswell Charles SVP & General Counsel Dec 22 Sale 380.29 322 122,453 3,283
TOUSI SUSAN H SVP, Chief Commercial Officer Dec 08 Sale 375.00 100 37,500 40,174
Dadswell Charles SVP, General Counsel Nov 22 Sale 377.86 314 118,648 3,605
Aravanis Alexander SVP, Chief Technology Officer Nov 12 Sale 386.35 361 139,472 4,127
Febbo Phillip G. SVP Chief Medical Officer Nov 08 Sale 406.83 1,000 406,830 3,015
Aravanis Alexander SVP, Chief Technology Officer Nov 02 Sale 412.78 2,926 1,207,801 4,679
TOUSI SUSAN H SVP, Chief Commercial Officer Oct 28 Sale 414.35 100 41,435 41,256
Aravanis Alexander SVP, Chief Technology Officer Oct 26 Sale 423.00 2,926 1,237,698 7,605
Dadswell Charles SVP & General Counsel Oct 22 Sale 411.00 314 129,054 4,658
Aravanis Alexander SVP, Chief Technology Officer Oct 19 Sale 411.82 2,926 1,204,972 10,531
Aravanis Alexander SVP, Chief Technology Officer Oct 12 Sale 409.21 2,926 1,197,350 13,457
TOUSI SUSAN H SVP, Chief Commercial Officer Sep 28 Sale 418.04 100 41,804 41,356
Dadswell Charles SVP & General Counsel Sep 22 Sale 436.69 314 137,121 4,972
TOUSI SUSAN H SVP, Chief Commercial Officer Aug 30 Sale 463.50 300 139,050 41,456
Dadswell Charles SVP & General Counsel Aug 23 Sale 489.10 314 153,577 5,286
TOUSI SUSAN H SVP, Chief Commercial Officer Aug 04 Sale 500.00 1,000 500,000 41,756
Hoyt Aimee L SVP, Chief People Officer Aug 04 Sale 500.00 372 186,000 3,757
TOUSI SUSAN H SVP, Chief Commercial Officer Jul 28 Sale 486.41 300 145,923 42,743
Dadswell Charles SVP & General Counsel Jul 22 Sale 482.23 314 151,420 5,576
Aravanis Alexander SVP, Chief Technology Officer Jul 07 Sale 477.59 539 257,421 4,679
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Cap:    |  Volume (24h):